International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) Meeting

2022 SPIN Congress Report Blog Graphic

The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 – Friday, July 8, 2022, in Paris, France. The SPIN congress is held every three years, with approximately 1,500 delegates from around 90 countries. It is a key event for patient management and therapeutic strategies with a special emphasis on the daily medical practice of psoriasis and other inflammatory skin diseases. Experts worldwide report on their experiences and deliver insight into the latest results and clinical studies. The following congress report includes twelve summaries of presentations focusing on psoriasis.  You can download the full report or read on for a brief look at some of the highlights.

SATELLITE SYMPOSIUM IPC – INTERNATIONAL PERSPECTIVES ON TREATING PSORIASIS

  • Nejib Doss provided a broad overview of the spectrum of topical therapies and alluded to the problem of treatment adherence. He also highlighted the effectiveness of less widely used topical therapies.
  • Lars Iversen shared insights on how and when to treat a patient when topical treatment is inappropriate. He also focused on the concept of early intervention.
  • In the panel discussion, Mark Bourcier (Canada), Andre Vicente Esteves de Carvalho (Brazil), Siew Eng Choon (Malaysia), and George-Sorin Tiplica (Romania) discussed how psoriasis is treated around the world.

GENERAL TOPICS

  • Wolf-Henning Boehncke presented Psoriasis – Why Does it Not Go for Good? and showed that high treatment goals have become more realistic for psoriasis, and even remission may sometimes be achieved. He also explained the role of tissue-resident memory T-cells about the recurrence of psoriasis lesions.
  • Hervé Bachelez presented Pustular Psoriasis: The Radiance of a Rare Auto-inflammatory Disease Model and took the audience through the path of discoveries and developments for pustular forms of psoriasis. He showed that generalized pustular psoriasis is associated with liver disease, and that multiple viruses can trigger flares of pustular psoriasis.
  • Lars Iversen presented Understanding the Pathophysiology of Psoriasis and Why it Becomes a Chronic Disease. He showed that short disease duration has been associated with a higher chance of super response op antipsoriatic drugs and further elaborated on the role of tissue-resident memory T-cells in the context of early intervention.
  • Alexander Egeberg presented Psoriasis: Registries and Drug Survival. He showed us that patients in the real world often have a long journey until a biologic is started and often ‘recycle’ therapy before biologic initiation. He also showed results of drug survival of biologics and small-molecule inhibitors in a Danish cohort of patients with psoriasis and other rheumatological diseases.
  • Arnon Cohen presented Registries and Safety – Herpes Zoster as an Example. He gave an overview of trial data on the differential risk of herpes zoster in patients using systemic therapies for psoriasis. Also, he showed several real-world data sources assessing this risk.
  • Elke de Jong presented Psoriasis: Registries and Patient Reported Outcomes. She showed that most patients on biologics have improvement of patient-reported outcomes (PROs), and that gender and age influence PROs. Furthermore, she showed data on the comparative risk for depression for different systemic psoriasis drugs.
  • Jonathan Barker presented An Introduction on Psoriasis and recaptured the genetic landscape of psoriasis. He showed the multiple (109) loci associated with psoriasis and explained why the psoriasis genome could also be called an ‘immunome’. He illustrated why genetic discoveries are so important for psoriasis drug development.
  • Peter van de Kerkhof presented Pathogenesis Based Treatments in Psoriasis. He showed the historical context of important discoveries in psoriatic disease and focused on the biologic in development – an IL36 inhibitor – for pustular psoriasis.
  • Juul van den Reek presented Psoriasis What Does the Future Hold? She gave an overview of the current psoriasis systemic treatments pipeline, with a special focus on remarkable compounds with new working mechanisms.
  • Deepak Balak presented Topical Innovations for Psoriasis. He focused on the most effective management when prescribing topical therapies and showed results of topical therapies in the pipeline.
  • Jo Lambert presented Psoriasis and Nutrition. She gave insight into the link between weight and psoriasis severity and the potential positive effects of intermittent fasting.
For a more in-depth read, please download the full report.
Categories
Tags
Recent Posts
BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

BMS Press Release Graphic

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Also Read

BIOMAP Collaboration Update A Systemic Review on Biomarkers
biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.